Lakefront Biotherapeutics (GLPGF) Cash from Investing Activities (2015 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Cash from Investing Activities for 12 consecutive years, with $72.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 19.23% year-over-year to $72.0 million in Q1 2026; TTM through Mar 2026 was $307.4 million, a 4.07% increase from a year earlier, with the FY2025 full-year figure at $326.3 million, up 36.67% from the prior year.
• Cash from Investing Activities was $72.0 million for Q1 2026 at Lakefront Biotherapeutics, down from $84.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $89.1 million in Q1 2025 and troughed at -$1.3 billion in Q4 2022.
• A 5-year average of -$147.0 million and a median of $71.1 million in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 273.75% in 2022 and soared 176.61% in 2025, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$1.3 billion in 2022, then soared by 106.47% to $82.2 million in 2023, then retreated by 11.14% to $73.0 million in 2024, then gained by 15.73% to $84.5 million in 2025, then declined by 14.83% to $72.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $72.0 million (Q1 2026), $84.5 million (Q4 2025), and $66.3 million (Q3 2025), per Business Quant data.